Bevy Of Regulatory Support Guides, Protects, And Accelerates Lonafarnib For Orphan Conditions
Read in-depth Eiger BioPharmaceuticals investment thesis (requires subscription)
Summarized Investment Thesis
My summarized investment thesis in Eiger BioPharmaceuticals (EIGR) is as follows:
- Lonafarnib, for progeria alone, nearly justifies Eiger's current valuation (~$50 million peak annual sales ((PAS)) potential + $50 million pediatric voucher upon regulatory approval (net valuation: 3.5x PAS + $50 million = $225 million)
- Lonafarnib for hepatitis delta virus ((HDV)) has demonstrated overt efficacy and safety for a disease with no FDA-approved therapies. More importantly, Eiger is a front-runner